LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 3 of total 3

Search options

  1. Article ; Online: Risk of COVID-19 in Patients with Cancer Receiving Immune Checkpoint Inhibitors.

    Klebanov, Nikolai / Pahalyants, Vartan / Murphy, William S / Theodosakis, Nicholas / Zubiri, Leyre / Klevens, R Monina / Kwatra, Shawn G / Lilly, Evelyn / Reynolds, Kerry L / Semenov, Yevgeniy R

    The oncologist

    2021  Volume 26, Issue 5, Page(s) e898–e901

    Abstract: ... among patients with cancer treated with immune checkpoint inhibitors (ICIs).: Materials and methods: This was ... susceptibility.: Conclusion: ICIs did not increase the rate of COVID-19. This information may assist patients ... a retrospective study of 1,545 patients with cancer treated with ICIs between July 1, 2019, and February 29, 2020, and ...

    Abstract Objective: The aim of this study was to determine the rate of coronavirus disease-19 (COVID-19) among patients with cancer treated with immune checkpoint inhibitors (ICIs).
    Materials and methods: This was a retrospective study of 1,545 patients with cancer treated with ICIs between July 1, 2019, and February 29, 2020, and 20,418 age-, sex-, and cancer category-matched controls in a large referral hospital system. Confirmed COVID-19 case and mortality data were obtained with Massachusetts Department of Public Health from March 1 through June 19, 2020.
    Results: The mean age was 66.6 years, and 41.9% were female. There were 22 (1.4%) and 213 (1.0%) COVID-19 cases in the ICI and control groups, respectively. When adjusting for demographics, medical comorbidities, and local infection rates, ICIs did not increase COVID-19 susceptibility.
    Conclusion: ICIs did not increase the rate of COVID-19. This information may assist patients and their oncologists in decision-making surrounding cancer treatment during this pandemic.
    MeSH term(s) Aged ; COVID-19 ; Female ; Humans ; Immune Checkpoint Inhibitors ; Male ; Massachusetts ; Neoplasms/drug therapy ; Retrospective Studies ; SARS-CoV-2
    Chemical Substances Immune Checkpoint Inhibitors
    Language English
    Publishing date 2021-04-17
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 1409038-7
    ISSN 1549-490X ; 1083-7159
    ISSN (online) 1549-490X
    ISSN 1083-7159
    DOI 10.1002/onco.13768
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4845: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 494: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: 826 Risk of COVID-19 infection among patients receiving immune checkpoint inhibitor therapy

    William Murphy / Leyre Zubiri / Kerry Reynolds / Vartan Pahalyants / Nikolai Klebanov / Nicholas Theodosakis / Monina Klevens / Evelyn Lilly / Yevgeniy Semenov

    Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl

    a tertiary care hospital system collaboration with the Massachusetts department of health

    2020  Volume 3

    Keywords Neoplasms. Tumors. Oncology. Including cancer and carcinogens ; RC254-282 ; covid19
    Language English
    Publishing date 2020-11-01T00:00:00Z
    Publisher BMJ Publishing Group
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  3. Article ; Online: Immune checkpoint inhibition in COVID-19: risks and benefits.

    Pezeshki, Parmida Sadat / Rezaei, Nima

    Expert opinion on biological therapy

    2021  Volume 21, Issue 9, Page(s) 1173–1179

    Abstract: ... augments the immune system response in COVID-19 patients with lymphopenia. However, ICI may also increase ... of COVID-19 among patients with cancer in general.: Areas covered: The immunomodulatory effects of ICI ... 2) infection. There is controversy over whether the severity of COVID-19 in cancer patients ...

    Abstract Introduction: Immune checkpoint inhibition (ICI) is a novel cancer immunotherapy, which is administered in patients with metastatic, refractory, or relapsed solid cancer types. Since the initiation of the Coronavirus Disease 2019 (COVID-19) pandemic, many studies have reported a higher severity and mortality rate of COVID-19 among patients with cancer in general.
    Areas covered: The immunomodulatory effects of ICI can modify the patients' immune system function in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. There is controversy over whether the severity of COVID-19 in cancer patients who previously received ICI compared to other patients with cancer has increased. There is evidence that the upregulation of immune checkpoint molecules in T cells, lymphopenia, and inflammatory cytokine secretion are associated with the severity of COVID-19 symptoms.
    Expert opinion: ICI can interrupt the T cell exhaustion and depletion by interrupting the inhibitory signaling of checkpoint molecules in T cells, and augments the immune system response in COVID-19 patients with lymphopenia. However, ICI may also increase the risk of cytokine release syndrome. ICI can be considered not only as a cancer immunotherapy but also as immunotherapy in COVID-19. More studies are needed to assess the safety of ICI in COVID-19 patients with or without cancer.
    MeSH term(s) Humans ; Immune Checkpoint Inhibitors/therapeutic use ; Pandemics ; Risk Assessment ; SARS-CoV-2 ; COVID-19 Drug Treatment
    Chemical Substances Immune Checkpoint Inhibitors
    Language English
    Publishing date 2021-02-17
    Publishing country England
    Document type Journal Article
    ZDB-ID 2052501-1
    ISSN 1744-7682 ; 1471-2598
    ISSN (online) 1744-7682
    ISSN 1471-2598
    DOI 10.1080/14712598.2021.1887131
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6094: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top